A PHASE 1/2 STUDY OF VADASTUXIMAB TALIRINE (SGN-CD33A) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) INTERMEDIATE-2 OR HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE 1/2 STUDY OF VADASTUXIMAB TALIRINE (SGN-CD33A) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) INTERMEDIATE-2 OR HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Seattle Genetics
Protocol Number
SGN 33A-004
Cancer Diagnosis
To Learn More Call
201-510-0910